rupiya.io
⠋Loading...
0%
❯ Reading balance sheets...
Divi's Labs is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Divis Laboratories Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Metric | 1 Year | 3 Years | 5 Years | 10 Years |
|---|---|---|---|---|
| Sales | — | — | — | — |
| Profit | — | — | — | — |
| Stock Price | — | — | — | — |
| ROE | — | — | — | — |
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹2,532 Cr | ₹3,115 Cr | ₹3,776 Cr |
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,708 Cr | ₹1,951 Cr | ₹1,778 Cr | ₹1,909 Cr | ||||||||
| Expenses | ₹1,299 Cr | ₹1,464 Cr | ₹1,274 Cr | ₹1,430 Cr | ||||||||
| Operating Profit | ₹409 Cr | ₹487 Cr | ₹504 Cr | ₹479 Cr |
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹27 Cr | ₹27 Cr | ₹53 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹2,937 Cr | ₹3,469 Cr | ₹4,240 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹557 Cr | ₹-305 Cr | ₹-248 Cr | — |
| Mar 2016 | ₹826 Cr | ₹-521 Cr | ₹-303 Cr | — |
| Mar 2017 | ₹1,038 Cr | ₹-406 Cr | ₹-631 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 |
| Ratio | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 14.4% | 15.4% | 14.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| ROCE % | 15.9% | 17.0% | 15.8% | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt/Equity | 0.6 | 0.5 | 0.6 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 10.1 | 8.4 | 7.0 | — | — | — | — | — | — | — | — | — | — |
| Year | Type | Amount (₹) |
|---|---|---|
| FY24 | Final | ₹9.89 |
| FY23 | Final | ₹14.45 |
| FY22 | Final | ₹14.82 |
| FY21 | Final | |
| FY20 | Final | |
| FY19 | Final |
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.53% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +1.47% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -3.21% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +26.02% |
| Torrent Pharmaceuticals Ltd | ₹1,49,446 Cr | 69.7 | 0.00% | +29.14% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.
Deep-dive analysis of Divi's Labs's competitive moat, management quality, and growth runway available with Premium.
Premium| Expenses | ₹1,514 Cr | ₹1,942 Cr | ₹2,354 Cr |
| Operating Profit | ₹1,018 Cr | ₹1,173 Cr | ₹1,423 Cr |
| OPM % | 40.0% | 38.0% | 38.0% |
| Other Income | ₹68 Cr | ₹38 Cr | ₹93 Cr |
| Depreciation | ₹92 Cr | ₹136 Cr | ₹118 Cr |
| Interest | ₹3 Cr | ₹3 Cr | ₹5 Cr |
| Profit Before Tax | ₹991 Cr | ₹1,072 Cr | ₹1,393 Cr |
| Tax | ₹991 Cr | ₹1,072 Cr | ₹1,393 Cr |
| Net Profit | ₹773 Cr | ₹852 Cr | ₹1,126 Cr |
| EPS (₹) | 29.1 | 32.1 | 42.4 |
| Dividend Payout % | 34% | 31% | 24% |
Register free to see 9 more years.
| OPM % | 24.0% | 25.0% | 28.0% | 25.0% |
| Depreciation | ₹87 Cr | ₹87 Cr | ₹93 Cr | ₹95 Cr |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Net Profit | ₹306 Cr | ₹321 Cr | ₹356 Cr | ₹348 Cr |
| EPS (₹) | 11.5 | 12.1 | 13.4 | 13.1 |
Register free to see 8 more quarters.
| Borrowings | ₹18 Cr | ₹27 Cr | ₹42 Cr |
| Other Liabilities | ₹729 Cr | ₹883 Cr | ₹562 Cr |
| Total Liabilities | ₹3,710 Cr | ₹4,405 Cr | ₹4,898 Cr |
| Assets |
| Fixed Assets | ₹1,222 Cr | ₹1,309 Cr | ₹1,439 Cr |
| Investments | ₹502 Cr | ₹733 Cr | ₹803 Cr |
| Receivables | — | — | — |
| Inventory | — | — | — |
| Cash & Equivalents | — | — | — |
| Other Assets | ₹1,842 Cr | ₹2,145 Cr | ₹2,392 Cr |
| Total Assets | ₹3,710 Cr | ₹4,405 Cr | ₹4,898 Cr |
Register free to see 9 more years.
| Mar 2022 |
| Mar 2023 |
| Mar 2024 |
| Mar 2025 |
Register free to see 9 more years.
| — |
| — |
| Current Ratio | 1.7 | 1.4 | 1.6 | — | — | — | — | — | — | — | — | — | — | — | — |
| Quick Ratio | 1.1 | 1.1 | 1.0 | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | 13.9% | 16.3% | 14.3% | — | — | — | — | — | — | — | — | — | — | — | — |
| NPM % | 8.3% | 9.8% | 8.6% | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 12.2 | 14.9 | 13.9 | — | — | — | — | — | — | — | — | — | — | — | — |
| PEG Ratio | 2.0 | 1.3 | 1.2 | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Turnover | 0.8 | 1.2 | 0.8 | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 9.2 | 10.1 | 7.7 | — | — | — | — | — | — | — | — | — | — | — | — |
Register free to see 12 more years of ratio trends.